Steven A. Vasilescu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steven A. Vasilescu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alexey S. Rzhevskiy
Institute of Molecular Theranostics, Sechenov First Moscow State Medical University, 119991 Moscow, Russia
1 shared publication - Alina Y. Kapitannikova
Institute of Molecular Theranostics, Sechenov First Moscow State Medical University, 119991 Moscow, Russia
1 shared publication - Andrei Vasilyevich Zvyagin
Scientific Center for Translational Medicine, Sirius University of Science and Technology, 354340 Sirius, Russia
1 shared publication - Denis V. Butnaru
Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
1 shared publication - Dmitry Enikeev
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
1 shared publication - Evgeniy V. Shpot
Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
Prostate cancer (PCa) diagnosis is primarily based on prostate-specific antigen (PSA) testing and prostate tissue biopsies. However, PSA testing has relatively low specificity, while tissue biopsies are highly invasive and have relatively low sensitivity at early stages of PCa. As an alternative, we developed a technique of liquid biopsy, based on isolation of circulating tumor cells (CTCs) from seminal fluid (SF). The recovery of PCa cells from SF was demonstrated using PCa cell lines, achieving an efficiency and throughput as high as 89% (±3.8%) and 1.7 mL min−1, respectively, while 99% (±0.7%) of sperm cells were disposed of. The introduced approach was further tested in a clinical setting by collecting and processing SF samples of PCa patients. The yield of isolated CTCs measured as high as 613 cells per SF sample in comparison with that of 6 cells from SF of healthy donors, holding significant promise for PCa diagnosis. The correlation analysis of the isolated CTC numbers with the standard prognostic parameters such as Gleason score and PSA serum level showed correlation coefficient values at 0.40 and 0.73, respectively. Taken together, our results show promise in the developed liquid biopsy technique to augment the existing diagnosis and prognosis of PCa.
Open AccessIsolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
Prostate cancer (PCa) diagnosis is primarily based on prostate-specific antigen (PSA) testing and prostate tissue biopsies. However, PSA testing has relatively low specificity, while tissue biopsies are highly invasive and have relatively low sensitivity at early stages of PCa. As an alternative, we developed a technique of liquid biopsy, based on isolation of circulating tumor cells (CTCs) from seminal fluid (SF). The recovery of PCa cells from SF was demonstrated using PCa cell lines, achieving an efficiency and throughput as high as 89% (±3.8%) and 1.7 mL min−1, respectively, while 99% (±0.7%) of sperm cells were disposed of. The introduced approach was further tested in a clinical setting by collecting and processing SF samples of PCa patients. The yield of isolated CTCs measured as high as 613 cells per SF sample in comparison with that of 6 cells from SF of healthy donors, holding significant promise for PCa diagnosis. The correlation analysis of the isolated CTC numbers with the standard prognostic parameters such as Gleason score and PSA serum level showed correlation coefficient values at 0.40 and 0.73, respectively. Taken together, our results show promise in the developed liquid biopsy technique to augment the existing diagnosis and prognosis of PCa.